Waijer SW, Vart P, Cherney DZ, Chertow GM, Jongs N, Langkilde AM, Mann JFE, Mosenzon O, Mcmurray JJ, Rossing P, Correa-Rotter R, Stefansson B, Toto RD, Wheeler DC, Heerspink HJL (2022)
Publication Type: Journal article
Publication year: 2022
DOI: 10.1007/s00125-022-05694-6
Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney disease, hospitalised heart failure or cardiovascular death, and death from all causes in patients with chronic kidney disease (CKD) with or without type 2 diabetes. Patients with more severe CKD are at higher risk of kidney failure, cardiovascular events and all-cause mortality. In this post hoc analysis, we assessed the efficacy and safety of dapagliflozin according to baseline Kidney Disease Improving Global Outcomes (KDIGO) risk categories.
APA:
Waijer, S.W., Vart, P., Cherney, D.Z., Chertow, G.M., Jongs, N., Langkilde, A.M.,... Heerspink, H.J.L. (2022). Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. https://doi.org/10.1007/s00125-022-05694-6
MLA:
Waijer, Simke W., et al. "Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial." Diabetologia (2022).
BibTeX: Download